Assessment of Novel Therapeutics for Individualized Breast Cancer Care in the Modern Era: The Role of Metformin in Breast Cancer Therapy Lauren M. Postlewait ASO Perspectives 12 October 2022 Pages: 1 - 3
Contralateral Prophylactic Mastectomy in Average Risk Women: Who Can Choose This Wisely? Suzanne B. Coopey ASO Perspectives 20 October 2022 Pages: 4 - 5
Screening MRI in Patients with High-Risk Breast Lesions: More May Not Necessarily be More Juan C. ParamoRoshni Rao Breast Oncology 25 September 2022 Pages: 6 - 7
Ensuring Both Accessibility and Usability of Breast Cancer Care SeungJu Jackie OhParis D. Butler Breast Oncology 07 November 2022 Pages: 8 - 9
Just a Little Bit of Anaplastic Thyroid Cancer? Electron Kebebew Endocrine Tumors 21 October 2022 Pages: 10 - 11
Invited Editorial on Surgical Treatment of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: Pay Close Attention to the Pathology Report Rodney F. Pommier Endocrine Tumors 04 November 2022 Pages: 12 - 14
Survival Benefit of Neoadjuvant Therapy for Extrahepatic Cholangiocarcinoma: Real or Artifact? Rebecca A. Snyder Pancreatic Tumors 10 August 2022 Pages: 15 - 17
Neoadjuvant Chemotherapy Plus Living Donor Transplantation (LDLT) for Non-Resectable Liver Metastases from Colorectal Cancer (CRC) Jacob LambdinCarrie E. RyanDavid P. Al-Adra ASO Research Letter 31 October 2022 Pages: 18 - 20
Selective Internal Radiation Therapy (Yttrium-90 Glass Microspheres) Combined with Capecitabine in the Neoadjuvant Setting of Operable Intrahepatic CHOlangiocarcinoma: The SIROCHO Trial Design Julien EdelineYan RollandKarim Boudjema ASO Research Letter 21 October 2022 Pages: 21 - 22
Effects of COVID-19 on Surgical Delays in Patients with Breast Cancer in NYC Public Hospitals: A Multicenter Study Natalie EscobarCharles DiMaggioKathie-Ann Joseph Global Health Services Research 15 September 2022 Pages: 23 - 30
ASO Author Reflections: Same but Different: Implications of Surgical Delays for Breast Cancer Patients Treated in NYC Public Hospitals During the COVID-19 Pandemic Natalie EscobarKathie-Ann Joseph ASO Author Reflections 05 October 2022 Pages: 31 - 32
ASO Visual Abstract: An Analysis of COVID-19 on Surgical Delays in Breast Cancer Patients in NYC Public Hospitals—A Multicenter Study Natalie EscobarCharles DiMaggioKathie-Ann Joseph ASO Visual Abstract 26 September 2022 Pages: 33 - 34
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium Jacek GlajzerDan Cacsire Castillo-TongElena Ioana Braicu Gynecologic Oncology Open access 09 September 2022 Pages: 35 - 45
ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy—Innovative Models Prolong Survival (OCTIPS) Consortium Jacek GlajzerDan Cacsire Castillo-TongElena Ioana Braicu ASO Visual Abstract 05 November 2022 Pages: 46 - 47
Landmark Series on Disparities: Uterine Cancer and Strategies for Mitigation Eloise Chapman-DavisEmily M. WebsterKevin Holcomb Gynecologic Oncology 14 November 2022 Pages: 48 - 57
The Landmark Series—Addressing Disparities in Breast Cancer Screening: New Recommendations for Black Women Oluwadamilola M. FayanjuChristine E. EdmondsKathie-Ann Joseph Breast Oncology 03 October 2022 Pages: 58 - 67
Screening MRI Does Not Increase Cancer Detection or Result in an Earlier Stage at Diagnosis for Patients with High-Risk Breast Lesions: A Propensity Score Analysis Alison LawsFisher KatlinTari A. King Breast Oncology 28 September 2022 Pages: 68 - 77
ASO Visual Abstract: Screening MRI Does Not Increase Cancer Detection or Result in Earlier Stage at Diagnosis in Patients with High-Risk Breast Lesions–A Propensity Score Analysis Alison LawsFisher KatlinTari A. King ASO Visual Abstract 12 October 2022 Pages: 78 - 79
Area Deprivation Index is Associated with Variation in Quality of Life and Psychosocial Well-being Following Breast Cancer Surgery Abbas M. HassanHuan T. NguyenAnaeze C. Offodile 2nd Breast Oncology 09 September 2022 Pages: 80 - 87
ASO Author Reflections: Neighborhood-Level Deprivation Impacts Patient-Reported Outcomes Following Breast Cancer Surgery Abbas M. HassanAnaeze C. Offodile 2nd ASO Author Reflections 10 October 2022 Pages: 88 - 89
ASO Visual Abstract: The Area Deprivation Index is Associated with Variation in Quality of Life and Psychosocial Well-being After Breast Cancer Surgery Abbas M. HassanHuan T. NguyenAnaeze C. Offodile II ASO Visual Abstract 20 September 2022 Pages: 90 - 91
Axillary Staging Is Not Justified in Postmenopausal Clinically Node-Negative Women Based on Nodal Disease Burden Minna K. LeeGiacomo MontagnaMonica Morrow Breast Oncology 25 July 2022 Pages: 92 - 97
ASO Visual Abstract: Axillary Staging Is Not Justified in Postmenopausal Clinically Node-Negative Women Based on Nodal Disease Burden Minna K. LeeGiacomo MontagnaMonica Morrow ASO Visual Abstract 28 September 2022 Pages: 98 - 99
Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy Elizabeth A. MittendorfOlga KantorTari A. King Breast Oncology 08 August 2022 Pages: 100 - 106
Evaluating Axillary Lymph Node Yield After Neoadjuvant Chemotherapy Betty FanKelsey RomatoskiTed James Breast Oncology 26 August 2022 Pages: 107 - 111
ASO Author Reflections: Expectations in Axillary Lymph Node Dissections After Neoadjuvant Chemotherapy Betty FanTed A. James ASO Author Reflections 08 October 2022 Pages: 112 - 113
ASO Visual Abstract: Evaluating Axillary Lymph Node Yield After Neoadjuvant Chemotherapy Betty FanKelsey RomatoskiTed James ASO Visual Abstract 13 November 2022 Pages: 114 - 114
Patient-Reported Outcome Measures for Patients Who Have Clinical T4 Breast Cancer Treated via Mastectomy with and Without Reconstruction Emily PalmquistJessica LimbergAudree B. Tadros Breast Oncology 23 September 2022 Pages: 115 - 121
ASO Author Reflections: The Decision to Pursue Reconstruction After Mastectomy in cT4 Patients Emily PalmquistAudree B. Tadros ASO Author Reflections 10 October 2022 Pages: 122 - 123
ASO Visual Abstract: Patient-Reported Outcome Measures in Patients with Clinical T4 Breast Cancer Treated with Mastectomy With and Without Reconstruction Emily PalmquistJessica LimbergAudree B. Tadros ASO Visual Abstract 07 October 2022 Pages: 124 - 125
Prepectoral Versus Subpectoral Implant-Based Breast Reconstruction: A Systemic Review and Meta-analysis Edvin OstapenkoLarissa NixdorfFlorian Fitzal Breast Oncology Open access 16 October 2022 Pages: 126 - 136
Coexisting Papillary and Anaplastic Thyroid Cancer: Elucidating the Spectrum of Aggressive Behavior Jacques A. GreenbergMaureen D. MooreBrendan M. Finnerty Endocrine Tumors 12 October 2022 Pages: 137 - 145
ASO Visual Abstract: Co-existing Papillary and Anaplastic Thyroid Cancer—Elucidating the Spectrum of Aggressive Behavior Jacques A. GreenbergMaureen D. MooreBrendan M. Finnerty ASO Visual Abstract 07 October 2022 Pages: 146 - 147
Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-analysis Ioannis A. ZiogasPanagiotis T. TasoudisJames R. Howe Endocrine Tumors 13 October 2022 Pages: 148 - 160
ASO Author Reflections: Surgical Resection Should be Considered in the Multidisciplinary Care of Patients with Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms Ioannis A. ZiogasJoseph S. DillonJames R. Howe ASO Author Reflections 08 October 2022 Pages: 161 - 162
ASO Visual Abstract: Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms—A Systematic Review and Meta-Analysis Ioannis A. ZiogasPanagiotis T. TasoudisJames R. Howe ASO Visual Abstract 15 November 2022 Pages: 163 - 164
Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periampullary Adenocarcinoma Mohamed Abdelgadir AdamAlexa GlencerAmer H. Zureikat Pancreatic Tumors 04 August 2022 Pages: 165 - 174
ASO Author Reflections: Neoadjuvant Therapy for Nonpancreatic Periampullary Adenocarcinoma Mohamed A. AdamAlexa C. GlencerAmir H. Zureikat ASO Author Reflections 26 July 2022 Pages: 175 - 176
ASO Visual Abstract: Neoadjuvant Therapy Versus Upfront Resection for Non-pancreatic Periampullary Adenocarcinoma Mohamed Abdelgadir AdamAlexa GlencerAmer H. Zureikat ASO Visual Abstract 31 October 2022 Pages: 177 - 178
Palliative Therapies in Metastatic Pancreatic Cancer: Does Medicaid Expansion Make a Difference? Hamza KhanDeepa CherlaAnnabelle L. Fonseca Pancreatic Tumors 28 September 2022 Pages: 179 - 188
ASO Author Reflections: Disparities in Receipt of Palliative Therapies for Pancreatic Cancer: Did Medicaid Expansion Help? Hamza KhanErrol D. CrookAnnabelle L. Fonseca ASO Author Reflections 16 October 2022 Pages: 189 - 190
ASO Visual Abstract: Palliative Therapies in Metastatic Pancreatic Cancer—Does Medicaid Expansion Make a Difference? Hamza KhanDeepa CherlaAnnabelle L. Fonseca ASO Visual Abstract 07 October 2022 Pages: 191 - 192
A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement Naoki IkenagaYoshihiro Miyasakafor the Kyushu Study Group of Treatment for Pancreatobiliary Cancer Pancreatic Tumors 07 October 2022 Pages: 193 - 202
ASO Author Reflections: Novel Evidence on Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer with Arterial Involvement Naoki IkenagaYoshihiro MiyasakaMasafumi Nakamura ASO Author Reflections 21 September 2022 Pages: 203 - 204
ASO Visual Abstract: A Prospective, Multicenter, Phase II, Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement Naoki IkenagaYoshihiro Miyasakafor the Kyushu Study Group of Treatment for Pancreatobiliary Cancer ASO Visual Abstract 28 September 2022 Pages: 205 - 206
CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Laura MagginoGiuseppe MalleoRoberto Salvia Pancreatic Tumors Open access 13 October 2022 Pages: 207 - 219
ASO Author Reflections: Recurrence Following Post-neoadjuvant Pancreatectomy: How Can We Do Better? Laura MagginoGiuseppe MalleoRoberto Salvia ASO Author Reflections 13 October 2022 Pages: 220 - 221
ASO Visual Abstract: Ca 19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Laura MagginoGiuseppe MalleoRoberto Salvia ASO Visual Abstract 04 November 2022 Pages: 222 - 223
Is There a Role for Adjuvant Chemotherapy in Pathologic Node-Negative Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation Therapy? Jessica M. KeilsonAdriana C. GamboaGlen C. Balch Colorectal Cancer 21 October 2022 Pages: 224 - 232
Identification of the Minimum Combination of Serum microRNAs to Predict the Recurrence of Colorectal Cancer Cases Yukihiro YoshikawaMitsuko FukunagaKoshi Mimori Colorectal Cancer Open access 29 September 2022 Pages: 233 - 243
